News

  • eNIOS was awarded the 1st prize of Pfizer’s accelerator Start4Health

    eNIOS was awarded the 1st prize of Start4Health, an accelerator organized by Pfizer’s Center of Digital Innovation. Start4Health focused on Digital Health and targeted startup companies that develop solutions that can tackle challenges of the health industry, improve the digital experience of patients and promote wellness through technology. eNIOS worked closely with the programme’s experts…

  • Analysis of biological big data in precision medicine and drug development (HEALTH by Next Deal, in Greek)

    Read the article here.

  • Regulated IRE1α-dependent decay (RIDD)-mediated reprograming of lipid metabolism in cancer (Nature Communications)

    Our new paper in Nature Communications, involving functional transcriptomic analysis with the e-NIOS BioInfoMiner platform. BioInfoMiner enables an automated data, but also biology-driven interpretation of omic data, making evident which are the crucial genes driving the phenotypes and how they are interacting. https://www.nature.com/articles/s41467-022-30159-0 Almanza A, Mnich K, Blomme A, Robinson CM, Rodriguez-Blanco G, Kierszniowska S,…

  • Integration of Raman spectra with transcriptome data in glioblastoma multiforme defines tumour subtypes and predicts patient outcome

    Glioblastoma Multiforme is the most aggressive form of primary brain tumors. Raman spectroscopy is an imaging technique that has been applied to assess molecular compositions of living cells to characterize cell types and states. However, owing to the diverse molecular species in cells and challenges of assigning peaks to specific molecules, it had not yet…

  • Integration of Raman spectra with transcriptome data in glioblastoma multiforme defines tumour subtypes and predicts patient outcome

    Glioblastoma Multiforme is the most aggressive form of primary brain tumors. Raman spectroscopy is an imaging technique that has been applied to assess molecular compositions of living cells to characterize cell types and states. However, owing to the diverse molecular species in cells and challenges of assigning peaks to specific molecules, it had not yet…

  • Award to e-NIOS by the HDB – Hellenic Development Bank SA and Researcher’s Night

  • Epigenetics in Breast Cancer Therapy-New Strategies and Future Nanomedicine Perspectives
    Epigenetics in Breast Cancer Therapy-New Strategies and Future Nanomedicine Perspectives

    e-NIOS is a partner of the international INNOCENT project, with the aim to develop an innovative multifunctional nano-pharmaceutical to overcome the low efficacy and frequent relapses in breast cancer treatment. The use of nano-based delivery systems, together with the benefits of a new generation of epi-drugs and the emergence of robust biomarker data, will help…

  • Announcement of BioS Online Seminars: Digital Skills on Computational Biology for Health Professionals, 15-16 October 2020

    Within the framework of the Erasmus days, the BioS project offers further online seminars on modules 1 to 3 to deepen and apply the knowledge acquired in the course. We would like to invite you to join us. https://www.erasmusdays.eu/event/bios-project/ To participate in the BioS Online Seminar, please register under: https://docs.google.com/forms/d/e/1FAIpQLSfBTZyQs3pFRskynuEkocOzqzW_vc5TeTodxWDlG375VvrqDg/viewform After registration, you receive the…

  • BioInfoMiner elucidates the role of the early secretory pathway in SARS-CoV-2 infection

    https://doi.org/10.1083/jcb.202006005 Here, we analyze and discuss the contribution of the molecular machines operating in the early secretory pathway in the biogenesis of SARS-CoV-2 and their relevance for potential antiviral targeting. The fact that these molecular machines are conserved throughout evolution, together with the redundancy and tissue specificity of their components, provides opportunities in the search…

  • RA-map: a state-of-the-art interactive knowledge base for rheumatoid arthritis

    RA-map is a fully annotated, expert validated, state-of-the-art knowledge base for RA in the form of a molecular map. BioInfoMiner was used for topological, functional and pharmacogenomic analysis. The publication is accessible at: Vidisha Singh, George D Kalliolias, Marek Ostaszewski, Maëva Veyssiere, Eleftherios Pilalis, Piotr Gawron, Alexander Mazein, Eric Bonnet, Elisabeth Petit-Teixeira, Anna Niarakis, RA-map:…

  • New publication on bioinformatic analysis of phage display experiments

    In this publication, we introduce PepSimili, an integrated workflow tool, which performs mapping of massive peptide repertoires on whole proteomes and delivers a streamlined, systems-level biological interpretation. https://www.frontiersin.org/articles/10.3389/fphys.2019.01160/full

  • New e-NIOS’ study links proteostasis with inflammation and suggests a therapeutic approach for Crohn’s disease (EMBO Molecular Medicine)
    New e-NIOS’ study links proteostasis with inflammation and suggests a therapeutic approach for Crohn’s disease (EMBO Molecular Medicine)

    Find our new paper here. The molecular mechanisms underlying inflammatory bowel diseases remain currently not completely understood, and therapeutic options are scarce. Herein, we have identified that a normally endoplasmic reticulum resident protein, AGR2, exhibits tightly regulated secretion mechanisms that are perturbed in Crohn’s disease. We demonstrate that the extracellular release of AGR2 leads to…

  • Join us at Bio-IT World 2019 Boston

    e-NIOS is excited to participate in Bio-IT World, 16-18 April 2019, Boston. Join us at Seven Bridges’ booth #332 in the Exhibit Hall, for a demonstration of signature-based interpretation on the Seven Bridges Platform with BioInfoMiner!  

  • Collaborative publication with DKFZ, ACCC and NHRF on Radiogenomics and Colorectal Cancer towards Precision Medicine

    This is a new e-NIOS’ collaborative work on composite biomarker signatures, combining genomics with positron emission tomography (PET) measurements. Online paper (open access) The Athens Comprehensive Cancer Center (ACCC) was founded in 2017, in partnership with  the German Cancer Research Center (DKFZ) (Heidelberg, Germany) and aims to position itself as the first comprehensive cancer center…

  • Seven Bridges, E-Nios Partner to Automate Biomarker Extraction From NGS Data (GenomeWeb)

  • Seven Bridges & e-NIOS Partnership to Break the Biomarker Bottleneck

    Press: GenomeWeb PR Newswire Cambridge, Mass. and Athens, Greece., Sept 11, 2018. Seven Bridges, the leading biomedical data platform and analytics company, and e-NIOS, a biological knowledge discovery start-up, announced a strategic partnership towards data-driven discovery of biomarker signatures. Derivation of robust biomarkers from next generation sequencing and multi-omic data is currently a major bottleneck…

  • Meet us at the ECCB 2018 Conference

    e-NIOS is excited to sponsor and participate in the 7th European Conference on Computational Biology, 8-12 September, 2018, Athens. ECCB is the main computational biology event in Europe and will welcome scientists working in a variety of disciplines, including bioinformatics, computational biology, biology, medicine, and systems biology. On Tuesday September 11, 2018 Eleftherios Pilalis, CTO,…

  • e-NIOS signature-based stratification presented at the PERMIDES Final Conference

    The joint project, entitled “Prioritization and pathway Analysis by MachinE LeArning”, between e-NIOS and Genosalut clinical genomics company, was presented at the PERMIDES Final Conference held on June 12, 2018, in Utrecht, The Netherlands, where fourteen of the best projects presented their results. The project aimed at the development of an innovative precision medicine application,…

  • New publication involving BioInfoMiner analysis suggests induction of IRE1α-dependent Anticancer Immunosurveillance by low-protein diet (Cell Metabolism)

    A new paper involving the participation of e-NIOS and a BioInfoMiner-derived biomarker signature was published in the high impact journal Cell Metabolism. Dietary restriction was shown to impact on tumor growth with very variable effects depending on the cancer type. However, how dietary restriction limits cancer progression remains largely unknown. In this publication,  we demonstrate…

  • New paper involving BioInfoMiner analysis validates proteostasis imbalance as a driver of tumor aggressiveness in Glioblastoma (EMBO Mol. Med.)

    Proteostasis imbalance is emerging as a major hallmark of cancer, driving tumor aggressiveness. Evidence suggests that the endoplasmic reticulum (ER), a major site for protein folding and quality control, plays a critical role in cancer development. This concept is valid in glioblastoma multiform (GBM), the most lethal primary brain cancer with no effective treatment. It was…

  • e-NIOS selected for participation in the PERMIDES project

    A joint project between e-NIOS and Genosalut genomics company is among the 25 best-ranked projects funded by a PERMIDES Innovation Voucher. The project, entitled “Prioritization and pathway Analysis by MachinE LeArning”, aims at the development of an innovative precision medicine application, which integrates clinical and computational expertise, as a decision support tool for diagnosis and…

  • “DISCOVER” Horizon 2020 research proposal approved

    e-NIOS will be joining soon another international interdisciplinary research network (Greece, Ireland, France, Switzerland, Turkey), which will bring together experts in the fields of immunology, cancer cell biology, systems biology and pre-clinical drug development, in order to investigate tumour – immune cell interactions for the development of new cancer therapies.

  • eNIOS joins the train-ERS H2020-funded innovation network

    eNIOS joins as partner organization the train-ERS H2020-funded innovation network, promoting the understanding of the Endoplasmic Reticulum Stress Response and the identification of innovative strategies for the treatment of ER stress-associated diseases: http://www.train-ers.eu/

  • Kick-off meeting of the INNOCENT consortium

    e-NIOS is a partner of the “INNOCENT” consortium (Slovakia, Greece, Norway, Spain, Latvia, ), funded by a EuroNanoMed II ERA-NET grant, aiming at the development of innovative multifunctional nanopharmaceuticals for breast cancer treatment, with emphasis on cancer stem cells.

  • e-NIOS joins IPEM 2017

    e-NIOS will be joining IPEM 2017 (www.ipem-market.com) at Palais des Festivals, Cannes, France, 25-27 January, as a part of the Greek delegation of innovative companies selected by EASME.

  • “INSPIRED” H2020 proposal approved for funding

    The Horizon 2020 proposal “INSPIRED”, with the participation of e-NIOS, has been approved for funding. The INSPIRED consortium is an international interdisciplinary network (Greece, Ireland, France, Germany, Chile, USA) with complementary expertise in molecular biology, medicinal chemistry, clinical disease, cell biology, bioinformatics and ‘omics’ technologies, with the objective to develop novel approaches for treatment of…

  • GenomeWeb article about e-NIOS

    Greek Firm e-NIOS Offering Computational Methods to Prioritize Gene Targets for Multiple Markets